Atypical chronic myeloid leukemia: A rare entity with management challenges

Prajwal Dhakal, Krishna Gundabolu, Catalina Amador, Supratik Rayamajhi, Vijaya Raj Bhatt

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis ≥13 × 109/l with circulating neutrophil precursors ≥10%, monocytes less than 10%, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20% and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalFuture Oncology
Issue number2
StatePublished - Jan 2018


  • actionable mutation
  • atypical chronic myeloid leukemia
  • decitabine
  • hematopoietic stem cell transplant
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Atypical chronic myeloid leukemia: A rare entity with management challenges'. Together they form a unique fingerprint.

Cite this